Rye, NY – According to filings with the U.S. Securities and Exchange Commission, Curemark is raising $50,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Joan Fallon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Curemark

Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders.  Curemark’s pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson’s disease.

To learn more about Curemark, visit http://curemark.com/

Contact:
Joan Fallon, Chief Executive Officer
914-925-3450
joan.fallon@curemark.com
https://www.linkedin.com/in/dr-joan-fallon-298a562/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved